TWi Announces ANDA Approval of Generic Procardia XL(R) Tablets 30 mg, 60 mg and 90 mg in the United States

 TWi Announces ANDA Approval of Generic Procardia XL(R) Tablets 30 mg, 60 mg
                        and 90 mg in the United States

PR Newswire

TAIPEI, April 7, 2014

TAIPEI, April 7, 2014 /PRNewswire/ -- TWi Pharmaceuticals, Inc., today
announces the ANDA approval of the generic equivalent to Procardia XL®
(Nifedipine) Extended Release Tablets, 30 mg, 60 mg and 90 mg, in the United
States. TWi has begun the launch preparation with its US distributor partner
and will begin marketing the product as soon as the launch preparation is
completed.

Procardia XL® 30 mg, 60 mg and 90 mg, Extended Release Tablets marketed by
Pfizer Inc and the generic equivalent pharmaceuticals marketed by other
companies, had annual combined sales of approximately $116 million in the
United States, according to IMS data as of December 2013.

About TWi Pharmaceuticals, Inc.

TWi Pharmaceuticals, Inc. is a leading specialty pharmaceutical company based
in Taipei, Taiwan, focusing on the development of high barrier generic
prescription products ranging from oral controlled release dosage form to
novel drug delivery systems including the utilization of nanoparticles,
transdermal, and polymeric oral delivery systems. Leveraging its internal
research and development capabilities, together with operational flexibility,
process development, manufacturing and regulatory expertise, TWi
Pharmaceuticals concentrates on products and technologies that present
significant barriers to entry or offer Paragraph IV first-to-file or
first-to-market opportunities in the United States. For more information of
TWi Pharmaceuticals, please visitwww.twipharma.com.

Contact:
Liru Yeh
Head of Investor Relations
Tel: +886-2-2657-3350
Email: liru.yeh@twipharma.com

SOURCE TWi Pharmaceuticals, Inc.

Website: http://www.twipharma.com
 
Press spacebar to pause and continue. Press esc to stop.